CYTK Cytokinetics, Incorporated

14.05
+0.00  (0%)
Previous Close 14.05
Open 14.10
Price To book 6.40
Market Cap 633.42M
Shares 45,083,000
Volume 424,990
Short Ratio 7.13
Av. Daily Volume 711,983

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated January 2016. Data are due 2H 2017.
CK-2127107
Spinal muscular atrophy (SMA)
Phase 3 commencement announced December 1, 2016.
Omecamtiv mecarbil GALACTIC-HF
Acute heart failure
Phase 3 data are due 4Q 2017.
Tirasemtiv - VITALITY
Amyotrophic lateral sclerosis (ALS)
Phase 2 initiated June 2016. Enrollment to continue in 2017.
CK-2127107
Chronic obstructive pulmonary disease (COPD)

Latest News

  1. Cytokinetics Announces Orphan Drug Designation for CK-2127107 for the Treatment of Spinal Muscular Atrophy
  2. Biotech Movers: Anika Up on Strong Analyst Ratings
  3. Cytokinetics to Hold Annual Meeting of Stockholders
  4. Cytokinetics Announces Pricing of Public Offering of Common Stock
  5. Cytokinetics Announces Proposed Public Offering of Common Stock
  6. Edited Transcript of CYTK earnings conference call or presentation 27-Apr-17 8:30pm GMT
  7. New Strong Sell Stocks for May 4th
  8. Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
  9. Cytokinetics Announces Results from Dose Escalation Phase of COSMIC-HF Presented at Heart Failure 2017
  10. Merger Buzz Drives Akorn to Top of Health Chart in April
  11. Cytokinetics reports 1Q loss
  12. Cytokinetics, Inc. Reports First Quarter 2017 Financial Results
  13. ETFs with exposure to Cytokinetics, Inc. : April 24, 2017
  14. Cytokinetics Added to S&P SmallCap 600
  15. Cytokinetics, Inc. – Value Analysis (NASDAQ:CYTK) : April 20, 2017
  16. Cytokinetics, Inc.: Leads amongst peers with strong fundamentals
  17. Cytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : April 19, 2017
  18. Biotech Industry Outperforming Major Indexes in 2017: Today's Research Reports on Arena Pharmaceuticals and Cytokinetics
  19. Why Cytokinetics, Inc. Jumped Higher Today
  20. Gigamon, CBL & Associates Properties and Cytokinetics Set to Join S&P SmallCap 600